Status:
UNKNOWN
Evaluation of HRQoL in Adult With Immune Thrombocytopenia in China
Lead Sponsor:
Shandong University
Collaborating Sponsors:
Qilu Hospital of Shandong University (Qingdao)
Jining Medical University
Conditions:
Immune Thrombocytopenia
Eligibility:
All Genders
14-90 years
Brief Summary
Immune thrombocytopenia (ITP) is a heterogeneous disorder with variable clinical symptomsHealth related quality of life (HRQoL) could be considered in ITP, as in numerous chronic diseases, as a method...
Detailed Description
Immune thrombocytopenia (ITP) is an autoimmune thrombocytopenic syndrome characterized by decreased platelet count and an increased risk of bleeding.The pathogenesis of ITP has been considered as auto...
Eligibility Criteria
Inclusion
- Meet the diagnostic criteria for immune thrombocytopenia.
- aged of 14-80 years.
- Need or do not need treatments.
Exclusion
- Patients have any concomitant disease that could impact their quality of life significantly such as mental disorders
- Severe medical condition (lung, hepatic or renal disorder) other than ITP. Unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure, uncontrolled hypertension or cardiac arrhythmia)
- Have a known diagnosis of other autoimmune diseases, established in the medical history and laboratory findings with positive results for the determination of antinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct Coombs test.
- Patients who are deemed unsuitable for the study by the investigator.
Key Trial Info
Start Date :
May 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2018
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT03324087
Start Date
May 1 2017
End Date
May 1 2018
Last Update
October 27 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shandong University Qilu hospital
Jinan, Shandong, China, 250012